Leuprolide acetate 22.5mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal ...

Leuprolide acetate 30mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area, ...

Find clinical guidance on Lupron Depot, including indications, dosing, safety, side effects and evidence-based insights for healthcare professionals.

ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...

ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...

LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...

ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA ...

Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...